<DOC>
	<DOCNO>NCT01760265</DOCNO>
	<brief_summary>Dysbetalipoproteinemia ( type III , Fredrickson 's classification ) rare metabolic disorder . It result defect clearance VLDL chylomicron remnant due homozygous APOE2 variant heterozygous APOE mutation , elevate plasma cholesterol triglyceride . As consequence derangement lipoprotein metabolism , dysbetalipoproteinemia predispose premature development atherosclerosis . However among population heterogeneity development cardiovascular complication determinant remain unclear actually . The aim investigator study evaluate intensity clinical atherosclerosis , identify determinant .</brief_summary>
	<brief_title>DARK STUDY `` DysbetalipoproteinemiA atheRoma Risk ''</brief_title>
	<detailed_description />
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type III</mesh_term>
	<criteria>apo E gene sequence CBE ( Centre de Biologie Est / Hospices Civils de Lyon / France ) laboratory Lyon December 2012 age &lt; 40 year refuse participation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>dysbetalipoproteinemia</keyword>
	<keyword>artery calcium score</keyword>
	<keyword>carotid intima medium</keyword>
	<keyword>ankle brachial index</keyword>
	<keyword>dysbetalipoproteinemic patient</keyword>
</DOC>